In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas
about
Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumoniaAntibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5' nuclease real-time PCR.Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmasHematoma and abscess formation caused by Mycoplasma hominis following cesarean sectionIn vitro activity of five quinolones and analysis of the quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan.In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.Mycoplasma pneumoniae and its role as a human pathogen.Role of biofilm formation in Ureaplasma antibiotic susceptibility and development of bronchopulmonary dysplasia in preterm neonates.Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.Effects of Traditional Chinese Medicine Qinbai Qingfei Concentrated Pellet on Cellular Infectivity of Mycoplasma pneumoniae.Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.Epidemiology of Ureaplasma urealyticum and Mycoplasma hominis in the semen of male outpatients with reproductive disorders.Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacyIn-vitro Antimycoplasmal Activity of Triclosan in Combination with Fluoroquinolones against Five mycoplasma Species.Levofloxacin in the treatment of community-acquired pneumonia.Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapyMycoplasma pneumoniae from the Respiratory Tract and Beyond.In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections.In vitro activities of erythromycin, tetracycline and levofloxacin alone and in dual combinations against ureaplasma spp.Antibiotic prophylaxis improves Ureaplasma-associated lung disease in suckling mice.Mycoplasma pneumoniae: A significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections.
P2860
Q33836759-AF523112-C4E5-438D-B1AC-E029E298B2B3Q34077056-E1002AE1-DEEF-4004-B88D-46B3F727AD3EQ34228320-B1F5539E-C2F1-497C-8245-60FA7CB17FE1Q34230978-5A820E6D-F75E-49F7-BDDC-BAFB49035A7BQ34574124-F2F205F3-120E-4FF4-BF06-E67B7EFFFCCCQ35168864-17555909-9E6C-4A9D-BB33-BA691BE20B46Q35607663-47ACBF49-C2F5-421F-86EE-0421931DCD32Q35920629-992B21BF-A9B2-4752-A3E8-557E05DC4DBEQ36691560-48E27BFF-E53A-4C88-B6B8-EFCAE8F01B18Q36785835-82484C41-66D4-49D3-B05B-E1B587D39552Q36932955-8EF7AF66-3FC0-4E58-BCA4-9AC9A09402E3Q36978977-AF832220-E3F9-4B50-8B53-D3D1BC3C9C2CQ37036562-6D0E7EAB-D3CD-456F-8CF3-FB9DA64B468AQ37108724-CB47C3A1-A2B9-48BA-8AB1-7EA5A9997144Q37263838-713EAEF8-5095-4C6F-964D-AD018A9178AEQ37268241-C36EC134-A01D-4BAF-9ED7-56B2DFE6EAC2Q37747381-C5631D45-2008-4CE8-9258-F8096C41D1CEQ38842229-DE694ED3-9C8F-458A-A541-426C64489C81Q39327219-9F74BF65-B75A-4B52-94EA-BD6526BDF148Q41269280-863EAC08-2FB3-47BF-AEEB-2F569733A768Q42747636-FB86A5AB-18DA-45A2-A90C-95AAAFB868DDQ43207762-2FD2262D-861C-4ECC-BAC8-975C32110E78Q43973484-B6422F29-0D0B-4E9A-8A04-44DC845A8A84Q46038541-6396A2EF-23EF-41A4-BFE6-315A653B876DQ55491171-CDE5985A-0EA9-4036-9E3A-3DD3F125BBD2
P2860
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
In vitro susceptibilities to a ...... an mycoplasmas and ureaplasmas
@ast
In vitro susceptibilities to a ...... an mycoplasmas and ureaplasmas
@en
In vitro susceptibilities to and bactericidal activities of garenoxacin
@nl
type
label
In vitro susceptibilities to a ...... an mycoplasmas and ureaplasmas
@ast
In vitro susceptibilities to a ...... an mycoplasmas and ureaplasmas
@en
In vitro susceptibilities to and bactericidal activities of garenoxacin
@nl
prefLabel
In vitro susceptibilities to a ...... an mycoplasmas and ureaplasmas
@ast
In vitro susceptibilities to a ...... an mycoplasmas and ureaplasmas
@en
In vitro susceptibilities to and bactericidal activities of garenoxacin
@nl
P2093
P2860
P1476
In vitro susceptibilities to a ...... an mycoplasmas and ureaplasmas
@en
P2093
Donna M Crabb
Ken B Waites
Lynn B Duffy
P2860
P304
P356
10.1128/AAC.47.1.161-165.2003
P407
P577
2003-01-01T00:00:00Z